Key Developments For Trinity Biotech PLC
Trinity Biotech PLC (TRIB.O) (Nasdaq)
Trinity Biotech plc Announces $6 million Of Cost Reduction Measures
Trinity Biotech plc announced cost reductions across its business enterprise. The impact of these cost reductions, which consist of a combination of head count and overhead reductions, will amount to approximately $6million in fiscal 2009. These savings will be substantially realized in the first quarter of 2009. In total the Company's headcount has been reduced by 70 full-time employees which equates to a reduction of approximately 10% of the overall work force.
Akers Biosciences, Inc Signs Distribution Agreement With Trinity Biotech plc
Trinity Biotech plc announced that Akers Biosciences, Inc has appointed the Company as a distributor of ABI's PIFA Heparin/Platelet Factor-4 Rapid Assay (HPF4) in the USA and German markets.
Trinity Biotech plc Announces Group Restructuring
Trinity Biotech plc announced a restructuring of its business activities. The main elements of this restructuring are; a reorganisation of the worldwide sales and marketing function; Streamlining the Haemostasis and Infectious Diseases product lines; Increased focus within Research and Development; Closure of the Swedish manufacturing facility; and A headcount reduction resulting in payroll savings of $5 million.
Trinity Biotech plc Announces FDA Clearance Of TRIstat Point-of-Care HbA1c Test
Trinity Biotech plc announced that the US Food and Drug Administration (FDA) has given clearance to market the rapid, point-of-care TRIstat HbA1c system. The TRIstat point-of-care platform is designed to measure HbA1c, also known as glycated hemoglobin, which is a measure of a patient's blood sugarcontrol over the previous two to three months.
Trinity Biotech plc Announces Management Appointments
Trinity Biotech plc announced that Brendan Farrell has been appointed as Chief Executive Officer. Kevin Tansley has been appointed Chief Financial Officer and Secretary to the Board of Directors. Ronan O'Caoimh has held the positions of both Chairman and Chief Executive Officer of the Company. Consequently Ronan O'Caoimh will assume the role of Executive Chairman.
